Guideline Recommendations and Safety Considerations for Hydroxyzine Use in Anxiety

First‑Line Pharmacologic Recommendations

The National Institute for Health and Care Excellence (NICE) recommends lorazepam as the first‑line medication for acute anxiety, prescribing 0.5–1 mg orally up to four times daily as needed (maximum 4 mg/24 h). This recommendation is based on guideline consensus and is classified as a strong recommendation. 1
For elderly or debilitated patients, NICE advises reducing lorazepam to 0.25–0.5 mg per dose with a maximum of 2 mg in 24 hours to minimise fall risk and sedation. This dosage adjustment reflects a precautionary recommendation for vulnerable populations. 1

First‑generation antihistamines such as hydroxyzine are associated with sedation and measurable performance impairment, which patients may not subjectively recognise, raising safety concerns for driving and occupational tasks. Evidence derives from clinical pharmacology studies indicating a moderate level of risk. 2
Elderly patients exhibit heightened sensitivity to the psychomotor effects of hydroxyzine, including increased fall risk and greater susceptibility to anticholinergic side‑effects. These findings are supported by geriatric safety research and suggest the need for caution in this population. 2

Hydroxyzine 10 mg administered every 6 hours on an as‑needed (PRN) basis may be appropriate solely for managing dermatologic pruritus associated with interleukin‑2 therapy, but it is not recommended for primary anxiety treatment. This indication is based on a recent oncology supportive‑care study and reflects a specific, limited use case. 3

Optimal assessment of response to hydroxyzine occurs after 1 week of scheduled dosing, which may make titration more challenging when used on a PRN basis, according to Praxis Medical Insights 4

The National Institute for Health and Care Excellence (NICE) recommends benzodiazepines, such as lorazepam 0.5-1 mg orally up to four times daily as needed, as first-line pharmacological treatment for acute anxiety, representing a more evidence-based approach than hydroxyzine 5, 6, 7
For elderly or debilitated patients, the NICE guidelines suggest reducing benzodiazepine doses to 0.25-0.5 mg (maximum 2 mg in 24 hours) 5

The use of hydroxyzine as a first-line agent should be avoided when benzodiazepines are appropriate and not contraindicated, due to the stronger guideline support for benzodiazepines in acute anxiety management, as noted by the BMJ and Praxis Medical Insights 4, 5